COVID-19 vaccine sales push Moderna past expectations in Q2

Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts. The company said that its Spikevax vaccine brought in $4.53 billion during the quarter. Analysts were looking for around $3.6 billion, according to FactSet. Moderna shares surged Wednesday after the company also announced another $3 billion share buyback plan. Moderna’s vaccine sales in the…

Read More